Sonic Healthcare : CEO Presentation Half Year Results to 31 December 2020Opens in a new Window

18 February 2021

The Manager - Listings

Australian Securities Exchange Limited Exchange Centre

20 Bridge Street SYDNEY NSW 2000

Via electronic lodgement

Dear Sir / Madam

CEO PRESENTATION - HALF-YEAR RESULTS TO 31 DECEMBER 2020

At 8.30am AEDT today, Dr Colin Goldschmidt, Chief Executive Officer, will host a presentation of Sonic Healthcare's results for the half-year ended 31 December 2020. The slides for that presentation are enclosed.

The release of this announcement was authorised by the Board of Sonic Healthcare Limited.

Yours faithfully

Sonic Healthcare Limited

Paul Alexander Company Secretary

SONIC HEALTHCARE LIMITED ABN 24 004 196 909 • LEVEL 22, GROSVENOR PLACE • 225 GEORGE STREET • SYDNEY • NSW 2000 • AUSTRALIA

LOCKED BAG 145 • NORTH RYDE • NSW 1670 • TELEPHONE[phone] • FACSIMILE [phone]

Financial and Operational Review

Half-year ended 31 December 2020

Colin Goldschmidt

CEO, Sonic Healthcare 18 February 2021

Forward-looking Statements

This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts and unexpected growth in costs and expenses. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements. The information provided in this presentation is based on and should be read in conjunction with the Appendix 4D released to the ASX on 18 February 2021 and may include earnings figures restated on a "constant currency" basis.

Headlines - H1 FY 2021

•  H1 FY 2021 results

  •  Revenue A$4,432 million (33% growth)

  •  EBITDA A$1,307 million (89% growth)

  •  Net profit A$678 million (166% growth)

•  COVID-19

  •  Sonic's COVID testing capability continues to play a crucial role in pandemic control

  •  >18 million COVID PCR tests performed to date in ~60 Sonic laboratories globally

  •  Sonic's 37,000 staff providing vital testing for countries in which we operate

  •  Significant revenue and earnings contribution from COVID-19 testing, leveraging existing infrastructure

  •  Global base business revenue (ex-COVID testing) H1 FY 2021 down 1% vs H1 FY 2020 (constant currency), significantly less impacted than in first months of pandemic

•  Strong balance sheet

  •  Gearing at record low level

  •  Available liquidity ~A$1.3 billion (pre-interim dividend)

•  Progressive dividend strategy maintained

  •  Interim dividend $0.36 per share